Search research articles
Contact Us
Filters
Showing results (171-180 of 323) with videos related to
Page
of 33
Sort By:
British Journal of Haematology
|
November 22, 2018
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib
Matthew P Cheng, Amanda E Kusztos, Joshua N Gustine, et al.
Leukemia & Lymphoma
|
June 11, 2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells
Jenny Y Sun, Hsiuyi Tseng, Lian Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 23, 2002
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Nicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
Steven P Treon, Linda M Pilarski, Andrew R Belch, et al.
Clinical Lymphoma & Myeloma
|
February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
Evdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248
Steven P Treon, Zachary R Hunter, Jeffrey Matous, et al.
Blood
|
November 18, 2021
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM
Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2016
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
Steven P Treon, Kirsten Meid, Christina Tripsas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia
Irene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Page
of 33
Search research articles
Search
Showing results (171-180 of 323) with videos related to
Sort By:
Page
of 33
British Journal of Haematology
|
November 22, 2018
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib
Matthew P Cheng, Amanda E Kusztos, Joshua N Gustine, et al.
Leukemia & Lymphoma
|
June 11, 2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells
Jenny Y Sun, Hsiuyi Tseng, Lian Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial
Judith Trotman, Christian Buske, Alessandra Tedeschi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 23, 2002
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Nicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
Steven P Treon, Linda M Pilarski, Andrew R Belch, et al.
Clinical Lymphoma & Myeloma
|
February 28, 2007
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
Evdoxia Hatjiharissi, Mark Hansen, Daniel Ditzel Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248
Steven P Treon, Zachary R Hunter, Jeffrey Matous, et al.
Blood
|
November 18, 2021
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM
Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 13, 2016
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)
Steven P Treon, Kirsten Meid, Christina Tripsas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia
Irene M Ghobrial, Fangxin Hong, Swaminathan Padmanabhan, et al.
Page
of 33